Microsoft word - rm-cv 2007.doc

Mayeux -1
Richard Mayeux, MD, MSc
Gertrude H. Sergievsky Professor of Neurology, Psychiatry and Epidemiology

Work Address: 630 West 168th Street New York, NY 10032 [email protected]
Personal Data
Date and Place of Birth:

October 16, 1988 to Nancy S. Green, MD, 2 daughters, Naomi Beth and Sophie Ester
1964 - 1968
Bachelor of Science, Mammalian Physiology, Oklahoma State University Medical Doctor, Oklahoma University School of Medicine Masters of Science in Epidemiology, Columbia University School of Public Health
Post Graduate Training:

1972 - 1974
Internship & Residency: Boston City Hospital, Boston University, Internal Medicine. Residency: Columbia Presbyterian Medical Center, Neurology, Columbia University, College of Physicians and Surgeons Fellowship: Behavioral Neurology and Aphasia, Boston Veteran's Administration Hospital. Advanced Linkage Analysis, Columbia University Genetic Epidemiology and Molecular Biology (Summer Institute), Johns Hopkins
Board Qualification:

Medical License:

Chronology of Professional Employment:

1977 - 1978
Instructor in Neurology, Boston University School of Medicine Assistant Professor of Clinical Neurology, College of Physicians and Surgeons Assistant Attending: The Presbyterian Hospital (in New York City) Associate Professor of Clinical Neurology, Associate Attending: The Presbyterian Hospital (in New York City) Associate Professor of Clinical Psychiatry Associate Program Director, General Clinical Research Center College of Physicians & Surgeons Director, Division of Behavioral Neurology, Department of Neurology Co-Director, Taub Alzheimer’s Disease Research Center Mayeux -2

1985 -
Director, Memory Disorders Clinic, The New York State Psychiatric Institute Professor of Neurology and Psychiatry, Columbia University, College of Physicians & Surgeons. Attending Neurologist: The Presbyterian Hospital (in New York City) Gertrude H. Sergievsky Professor of Neurology and Psychiatry and Director, Gertrude H. Sergievsky Center Gertrude H. Sergievsky Professor of Neurology, Psychiatry and Epidemiology. Co-Director, Taub Institute for Research on Alzheimer’s Disease and the Aging Brain. Gertrude H. Sergievsky Professor of Neurology, Psychiatry and Epidemiology (in the Sergievsky Center and the Taub Institute). Director, Human Genetic Resources Core, Columbia University
Distinguished Graduate of Oklahoma University School of Medicine Leadership and Excellence in Alzheimer’s Disease Award (LEAD), National Institute of Aging Rita Hayworth Award, Alzheimer’s Association Dean’s Award, Columbia University, Distinguished Clinical Scientist Association of American Physicians American Epidemiological Society Institute of Medicine, National Academies of Science Distinguished Achievement Award, Isabella Geriatric Nursing Center Visiting Professor, Rockefeller University, Laboratory of Statistical Genetics Nancy R. McCune Research Award for Alzheimer’s Disease Potamkin Prize for Research in Pick's, Alzheimer's, and Related Diseases,
Honorific Lectures:
Joseph M. Foley, MD Lecturer, Case Western School of Medicine. Taylor Lecturer in Neurology and Psychiatry. University of Maryland. Bernard Siskind Lecturer, Lennox Hill Hospital, New York Robert Aird Visiting Professor, University of California at San Francisco Emanuel Goldberg Lecture, University of Rochester Mayeux -3
Decade of the Brain Plenary Presentation, American Academy of Neurology The JJ Silversides Lectureship in Clinical Neuroscience, University of Toronto Middelton-Goldsmith Lecture (New York Pathological Society) American Psychiatric Association, Frontiers in Science Lecture. Szabo Science Lecture, Hackley School, Tarrytown, New York Norman Geschwind Memorial Lecture, Harvard Medical School Boston, MA
Professional Organizations:
1977 - 1997
Associate, American Academy of Neurology. Scientific Issues Committee, American Academy of Neurology Clinical Research Subcommittee, American Academy of Neurology. Parkinson's Disease Epidemiology Research Committee. American Neurological Association, Ethical Affairs, Chairman Counselor, American Neurological Association. Association for Research in Nervous and Mental Disease International Genetic Epidemiology Society
Extramural Funding: Grants & Research Awards:
1977 - 1978
Post Doctoral Fellowship Award, NS05773. R0-1-AG-02802 Behavioral/Biochemical Correlation in Disease of Aging. Principal Investigator P50-MH43520 (HIV Center) HIV Center for Clinical and Behavioral Studies, Neurology Core Director Sigma Tau, L-acetyl carnitine in Alzheimer's Disease, Principal Investigator R0-1-NS26179 Mechanisms and Syndromes of Dementia Related to Stroke, Co-Principal investigator. R0-1-AG-05433 rCBF in Alzheimer's Disease., co-principal Investigator R0-1-AZ/MH44959, Behavioral Correlates of Magnetic Resonance Imaging in HIV, Principal Investigator. Dana Consortium on Memory. Principal Investigator, Changes in Memory During Normal Aging. U10-NS31321 Twin Studies in Parkinson's Disease. Co-Investigator . Dana Consortium on the Recognition and Treatment of AIDS Dementia and Related Disorders. Co-Principal Investigator. R01-AG07370, Predictors of Disease Severity in Alzheimer's disease, Co-Principal Investigator R35-AG10963 Leadership and Excellence in Alzheimer's Disease. Gene-Environment Interactions in Alzheimer's disease, Principal Investigator. Mayeux -4
R01-NS32527 Case-Control Study of Parkinson's Disease in the Elderly. Principal Investigator. P50-NS38370. Udall Parkinson’s Disease Research Center. Project 6, Principal Investigator. Gender and Ethnic Differences in Mortality for Parkinson’s Disease. R01-AG/ES18732 Genetic Epidemiology of Aging in a Multiethnic Community. Principal Investigator P50 AG08702 Coordinator of the National Institute of Aging, Alzheimer’s Disease Genetic Initiative for Late-Onset Alzheimer’s Disease. Administrative Director. Fine Mapping of Chromosomes 12 and 10 in Familial Alzheimer’s Disease. Principal Investigator. Alzheimer Association.

1983 -
Charles Robertson Memorial Gift for Research in Alzheimer's Disease from the Banbury Fund. The Henry and Marilyn Taub Foundation. Taub Center for Alzheimer’s Disease Research. Co-Director. Blanchette Hooker Rockefeller Fund for Research In Alzheimer’s Disease. Principal Investigator.
National Institutes of Health
1989 -
P01 AG07232 The Epidemiology of Dementia in an Urban Community, Principal Investigator. P50 AG08702 Alzheimer's Disease Research Center, Co-Director. R37 AG15473 Genetic Epidemiology of Alzheimer’s Disease in Hispanics. Principal Investigator. U01 AG023749 Multicenter Study on Exceptional Survival in Families. Principal Investigator U24 AG026395-01 Genetic Consortium for Late Onset Alzheimer's Disease. Principal Investigator
Departmental, University & Hospital Committees:
1978 - 1992
Executive and Residency Selection Committee, Department of Neurology University Senate: Medical School Faculty Internal Review Committee, General Center for Clinical Research Mayeux -5
Chairman, Search Committee Ophthalmology Human Genome Project Committee, Columbia University Tenure Review Advisory Committee, Columbia University Chairman, Search Committee Biostatistics, School of Public Health Chairman, Task Force on Human Genetics, Columbia University
Teaching Responsibilities:

1979 - 2001
Attending, Neurological Institute of New York, weekly Behavioral Neurology rounds, Harlem Hospital Center Behavioral Neurology rounds (monthly) Neuroscience course: Aphasia, Alexia and Apraxia lecture Neuroscience Review Course: Language Disorders and Aphasia. American Academy of Neurology, Course Director, Aging and Dementia. American Academy of Neurology, Clinical Research Methods Columbia University Medical School, Epidemiology (first-year)
Fellows and Current Academic Positions:
1982 - 1984
Yaakov Stern, PhD., Professor in Neurology & Psychiatry, Columbia University+
Mary Sano, Ph.D., Associate Professor in Neurology, Columbia University +
Armondo Schmit. MD, Professor in Psychiatry, Director Geriatric Psychiatry, Brown University Karen Marder, MD,MPH, Associate Professor in Neurology Columbia University.+
Karen Bell, MD, Assistant Professor in Neurology, Columbia University. George Dooneief, MD,MPH, Assistant Professor in Neurology, Columbia University. Rafael Lantigua, MD, Professor in Clinical Medicine, Columbia University.+
Ned Sacktor, MD, Instructor, Johns Hopkins School of Medicine+ Peter William Schofield,BSc (Hons), MBBS, MSc, MD, FRACP, Associate Professor of Psychiatry, University of Newcastle, Newcastle, Austrialia+ Michael Chun, MD, University of Washington, Assistant Professor of Neurology. Giancarlo Logroscino, MD, PhD. Associate Professor of Epidemiology. Harvard chool of Public Health Gayatri Devi, MD, Director, New York Memory Center Elan Louis, MD, MSc, Assistant Professor, Columbia University, Department of Neurology, Sergievsky Center + Veronica Hinton, Ph.D. , Assistant Professor of Neuropsychology (in Neurology and
the Sergievsky Center) , Columbia University. +
Leo Stefanis, MD, Assistant Professor of Neurology. Application of tropic factors to model systems of neuronal cell death.+ Carole Merchant, MD, MPH Assistant Professor of Neurology. Scott Small, MD, Assistant Professor of Neurology. Neurology.+ Stavra Romas, MD. Assistant Professor of Neurology. Neurology. Holly Posner, MD. Neuroepidemiology, Pfizer Mark Albers, MD, PhD. Assistant Professor of Neurology+. Christiana Reitz, MD. Vascular contribution to Alzheimer’s disease. Mayeux -6
Beverly Johnson, MD. Doris Duke Fellow (Genetics of Alzheimer’s Disease) (+) indicates successful independent funding for research.

National Committees

1998 – 2000
Council Member, American Neurological Association Long-Term Planning Committee, American Neurological Association Scientific Program Advisory Committee, American Neurological Association
Institute of Medicine

2001 – 2003
Gulf War and Health Committee II. Solvents and Pesticides, (Chair, Neurology Section) Gulf War and Health Committee III. Fuels, Combustion Products and Propellants, (Chair, Neurology Section) Gulf War and Health Committee, Updated Review on Sarin Physiologic, Psychologic and Psychosocial Effects of Deployment Stress (Chair) Membership committee, Section 7 (Neurology and Psychiatry)
Masters Candidates in Epidemiology
1993 - 1994
Giancarlo Logroscino, MD: Dietary Factors in Parkinson's Disease. Susan Titlebaum, PhD: Smoking and Alzheimer's Disease. Peter William Schofield, MSc. Head Injury and Alzheimer’s Disease.
Doctor of Public Health Candidate in Epidemiology
1995 - 1997
Giancarlo Logroscino, MD, PhD: Parkinson’s Disease.
Editorial Boards:
1985 - 1990

Bibliography: An asterisk after the citation denotes Dr. Mayeux as the senior author.

Original Articles:

Mayeux -7

1) Mayeux R, Brandt J, Rosen J, Benson F: Interictal memory and language impairment in temporal lobe
epilepsy. Neurology 1980; 30: 120-6.
2) Mayeux R, Stern Y, Rosen Y, Leventhal J: Depression, intellectual impairment and Parkinson disease.
Neurology 1981; 31:645-50.*
3) Matison R, Mayeux R, Rosen J, Fahn S: Tip-of-the-tongue phenomenon in Parkinson disease.
Neurology 1982; 32:567-70.
4) Mayeux R, Stern Y, Rosen J, Benson DF: Subcortical dementia: A recognizable clinical entity. Trans
Am Neuro Assoc 1981; 106:313-16.
5) Stern Y, Mayeux R, Rosen J, Ilson J: Perceptual motor dysfunction in Parkinson's disease. J Neurol,
Neurosurg, Psych 1983; 46: 145-51.*
6) Reed E, Lewison A, Mayeux R, Such-Foca N: HLA antigens in Parkinson's disease. Tissue Antigens
1983; 21:161-3.
7) Reed E, Lewison A, Mayeux R, Sucin-Foca N: HLA antigens in Alzheimer's disease. Tissues
Antigens 1983; 164-7.
8) Mayeux R, Stern Y, Rosen J. Benson DF: Is "subcortical dementia" a recognizable clinical entity?
Ann Neurol 1983; 14:278-83.
9) Stern Y, Mayeux R, Ilson J, Fahn S, Cote L: Pergolide treatment of Parkinson's disease:
Neurobehavioral changes. Neurology 1984; 34:201-3.*
10) Nerl C, Mayeux R, O'Neill JG: HLA-linked complement markers in Alzheimer's and Parkinson's
disease: C4 variant (C4B2) a possible marker for senile dementia of the Alzheimer's type. Neurology
1984; 34:310-14.*
11) Mayeux R, Cote L, Stern Y, Williams JBW: Altered serotonin metabolism in depressed patients with
Parkinson's disease. Neurology 1984; 34: 642-46.*
12) Stern Y, Mayeux R, Cote L: Reaction time and vigilance in Parkinson's disease: possible role of
altered norepinephrine metabolism. Arch Neurol 1984; 41:1086-9.*
13) Stern Y, Mayeux R, Rosen J: Contribution of perceptual motor dysfunction to construction and
tracing disturbances in Parkinson's disease. J Neurol Neurosurg Psychiat 1984; 47:983-94.*
14) Mayeux R, Stern Y, Spanton S: Heterogeneity in dementias of the Alzheimer type: Evidence for
subgroups. Neurology 1985;35:453-6l.*
15) Kaplan JG, Katzman R, Horoupian BS, Fuld PA, Mayeux R, Hays AP: Progressive dementia, visual
deficits, amyotrophy and micro infarcts. Neurology 1985, 35:789-96.
16) Mayeux R, Stern Y, Mulvey R, Cote L: A reappraisal of temporary Levodopa withdrawal ("Drug
Mayeux -8

Holiday") in Parkinson's disease. N Engl J Med 1985;313:724-8.*
17) Mayeux R, Stern Y, Williams JBW, Cote L, Frantz A, Dreyenfurth I. Clinical and biochemical
features of depression in Parkinson's disease. Am J Psychiatry, 1986; 143:756-9.*
18) Mayeux R, Stern Y, Hermann A, Greenbaum L, Fahn S: Correlates of early disability in Huntington's
disease. Ann Neurol 20:727-31, 1986.*
19) Mayeux R, Stern Y, Sano M. Heterogeneity and prognosis in dementia of the Alzheimer type. Clin
Neurosi Bull 1985; 50:7-10.*
20) Mayeux R, Albert M, Jenike M. Physostigmine-induced myoclonus in Alzheimer's disease.
Neurology. 1987;37:345-6.*
21) Whitehouse PJ, Vale WW, Zweig RM, Singer H, Mayeux R, Kuhar MY, Price OL, DeSoaza EB:
Reductions in corticotropin releasing factor-like immunoreactivity in cerebral cortex in Alzheimer's
disease, Parkinson's disease and progressive supranuclear palsy. Neurology 1987;37:905-9.
22) D'Amato RJ, Zweig RM, Whitehouse PJ, Wenk GL, Singer HS, Mayeux R, Price DL, Snyder SH:
Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurology 1987;22:229-36.
23) Stern Y, Sano M, Mayeux R. Effects of oral physostigmine in Alzheimer's disease. Ann Neurol
24) Stern Y, Mayeux R, Sano M, Hauser WA, Bush T: Predictors of disease course in patients with
probable Alzheimer's disease. Neurology 1987;37:1649-53.*
25) Mayeux R, Stern Y, Sano M, Cote L, Williams DSW: Clinical and biochemical correlates of
bradyphrenia in Parkinson's disease. Neurology 1987;37:1130-4.*
26) Dickson DW, Davies P, Mayeux R, Crystal H, Horoupian DS, Thompson A, Goldman JE: Diffuse
Lewy Body Disease, neuropathological and biochemical studies of six patients. Acta Neuropathol (Berl)
27) Mayeux R, Stern Y, Rosenstein R, Marder K, Hauser A, Cote L, Fahn S: An Estimate of the
prevalence of dementia in idiopathic Parkinson's disease. Arch Neurol 1988;45:260-2.*
28) Prohovnik I, Mayeux R, Sackheim H, Smith G, Stern Y, Alderson P: Cerebral Perfusion as a
Diagnostic Marker of Early Alzheimer's Disease. Neurology 1988;38:931-7.*
29) Stern Y, Mayeux R, Hermann A, Rosen J: Prism adaptation in Parkinson's disease. J Neurol
Neurosurg Psychiat 1988;51:1584-7.*
30) Duffy P, Mayeux R, Kupsky W: Familial Alzheimer's Disease with Myoclonus and "Spongy
Change." Arch Neurol 1988;45: 1097-1103.*
31) Devanand DP, Sackeim HA, Mayeux R. Psychosis, Behavioral Disturbance and the Use of
Neuroleptics in Dementia. Comp Psychiatry 1988; 29: 387-401.*
Mayeux -9

32) Mayeux R, Stern Y, Sano M, William JBW, Cote L. The relationship of serotonin to depression in
Parkinson's disease. Movement Dis 1988;3: 237-44.*
33) Stern Y, Sano M, Mayeux R. Long-term Administration of oral physostigmine in Alzheimer's
disease. Neurology, 1988;38: 1837-41.*
34) Mayeux R, Stern Y, Hesendorf D, Sano M. Noncognitive manifestations of Alzheimer's disease. Bull
Clin Neuroscience 1988; 53:10-4.*
35) Prohovnik I, Smith G, Sackeim HA, Mayeux R, Stern Y. Gray-matter degeneration in presenile
Alzheimer's disease. Ann Neurol 1989; 25: 117-24.*
36) Dal Pan G, Sano M, Stern Y, Mayeux R. Clock drawing in neurological disorders. Behav Neurology
1989; 2: 39-48.*
37) Devanand D, Sackeim HA, Brown RP, Mayeux R. A pilot study of haloperidol treatment of
psychosis and behavioral disturbance in Alzheimer's disease. Arch Neurol 1989; 46: 854-7.*
38) Zweig RM, Jankel WR, Hedreen JC, Mayeux R, Price DL. The pedunculopontine nucleus in
Parkinson's disease. Ann Neurol 1989;26:41-6.
39) Sano M, Stern Y, Williams J, Cote L, Rosenstein R, Mayeux R. Co-existing dementia and
depression in Parkinson's disease. Arch Neurol 1989; 46:1284-7.*
40) Mayeux R, Sano M, Chen J, Tatemichi T, Stern Y. Heredity as a risk factor for Alzheimer's disease.
New Trends in Clin Neuropharm 1989; 3: 217-23.*
41) Marder K, Flood P, Cote L, Mayeux R. A pilot study of risk factors for dementia in Parkinson's
disease. Movement Dis 1990; 5: 156-61.*
42) Stern Y, Hesdorffer D, Sano M, Mayeux R. Measurement and prediction of functional capacity in
Alzheimer's disease. Neurology 1990; 40: 8-13.*
43) Sano M, Stern Y, Marder K, Mayeux R. A controlled trial of Piracetam in intellectually impaired
patients with Parkinson's disease. Movement Dis 1990; 5:230-234.*
44) Palmert MR, Usiak M, Mayeux R, Raskind M, Tourtelotte W, Younkin SG. The soluble derivatives
of the beta amyloid protein precursor in cerebrospinal fluid: Alterations in normal aging and in
Alzheimer's disease. Neurology 1990; 40: 1028-34.
45) St George-Hyslop PH, Haines JL, Farrer LA, Plinsky R, Van Broeckhoven C, Goate A, Crapper-
Mclachlan CR, Orr H, Bruni AC, Sorbi S, Rainero I, Foncin JF, Pollon D, Cantu J-M, Tupler R,
Voskesenskaya N, Mayeux R, and others. Genetic linkage studies suggest that Alzheimer's disease is not
a single homogenous disorder. Nature 1990; 347: 194-7.
46) Mayeux R, Chen J, Mirabello E, Marder K, Bell K, Dooneief G, Stern Y. An estimate of the
incidence of dementia in patients with idiopathic Parkinson's disease. Neurology 1990; 40: 1513-7.*
Mayeux -10

47) Stern Y, Marder K, Bell K, Chen J, Dooneief G, Goldstein S, Mindry D, Richards M, Sano M,
Williams J, Gorman J, Ehrhardt A, Mayeux R. Multidisciplinary baseline assessment of gay men with
and without HIV infection: III. neurological and neuropsychological findings. Arch Psychiatry 1991;
48) Gorman J, Kertzner R, Todak G, Goetz R, Williams JBW, Rabkin J, Meyer-Bahlburg H, Mayeux R.
Stern Y, Lange M, Dobkin J, Spitzer R, Ehrhardt AA. Multidisciplinary baseline assessment of gay men
with and without HIV infection: I: Overview of Study Design. Arch Psychiatry 1991; 48:120-3.*
49) Mayeux R, Sano M, Chen J, Tatemichi T, Stern Y. Risk of dementia in first-degree family members
of patients with Alzheimer's disease and related disorders. Arch Neurol 1991; 48: 269-73.*
50. Marder K, Leung D, Tang M, Bell K, Dooneief G, Cote L, Stern Y, Mayeux R. Are demented
patients with Parkinson's disease accurately reflected in prevalence surveys? A survival analysis.
Neurology 1991; 41: 1240-4.*
51. Sano M, Stanley M, Lawton A, Cote' L, Williams JBW, Stern Y, Marder K, Mayeux R. 3H-
Imipramine binding: a peripheral marker for serotonin in Parkinson's disease. Arch Neurology 1991; 48:
52. Chen J, Stern Y, Sano M, Mayeux R. Cumulative risk of developing extrapyramidal signs, psychosis,
and myoclonus in the course of Alzheimer's disease. Arch Neurology 1991; 48: 1141-6.*
53. Richards M, Marder K, Bell K, Dooneief G, Mayeux R, Stern Y. Interrater reliability of
extrapyramidal signs in a group assessed for dementia. Arch Neurology 1991; 48: 1147-9.*
54. Gorman JM, Kertzner R, Cooper T, Goetz RR, Lagomasino I, Novacenko H, Williams JBW, Stern Y,
Mayeux R, Ehrhardt AA: Glucocorticoid level and neuropsychiatric symptoms in homosexual men with
HIV infection. Am J Psychiatry 1991; 148: 41-5.
55. Dooneief G, Bello J, Todak G, Mun I, Hilal S, Gorman J, Stern Y, Mayeux R. A prospective study of
magnetic resonance imaging in Human Immunodeficiency Virus. Arch Neurol 1992; 49:38-43.*
56. Devanand DP, Miller L, Richards M, Marder K, Bell K, Mayeux R, Stern Y. The Columbia
University Scale for Psychopathology in Alzheimer's Disease. Arch Neurol 1992; 49: 371-376.*
57. Dooneief G, Mirabello E, Bell K, Marder K, Stern Y, Mayeux R. An Estimate of the Incidence of
Depression in Idiopathic Parkinson's Disease. Arch Neurol 1992; 49: 305-7.*
58) Stern Y, Andrews H, Pittman J, Sano M, Tatemichi T, Lantigua R, Mayeux R. Diagnosis of dementia
in a heterogenous population: Development of a neuropsychological paradigm and quantified correction
for education. Arch Neurol 1992; 49: 453-60.*
59) Pittman J, Andrews H, Tatemichi T, Link B, Struening E, Stern Y, Mayeux R. Diagnosis of dementia
in a heterogeneous population: A comparison of paradigm based diagnosis and physician's diagnosis.
Arch Neurol 1992; 49: 461-7.*
Mayeux -11

60) Mayeux R, Denaro J, Hemenegildo N, Marder K, Tang MX, Cote LJ, Stern Y. A Population-Based
Investigation of Parkinson's Disease with and without Dementia: Relationship to age and gender. Arch
Neurol 1992; 49: 492-497.*
61) Tatemichi T, Desmond D, Mayeux R, Paik M, Stern Y, Sano M, Remien R, Williams JBM, Mohr J,
Hauser A, Figueroa M. Dementia after Stroke: Prevalence, risks, and baseline clinical features in a
hospitalized cohort. Neurology 1992; 42; 1185-1193.*
62) Stern Y, Alexander G, Prohovnik I, Mayeux R. Inverse relationship between education and
parietotemporal perfusion deficit in Alzheimer's disease. Ann Neurol 1992; 32: 371-375.*
63) Sano M, Bell K, Cote L, Dooneief G, Lawton A, Legler L, Marder K, Naini A, Stern Y, Mayeux R.
Double-blind parallel design pilot study of Acetyl-l-Carnitine in patients with Alzheimer's disease. Arch
Neurol 1992; 49:1137-1141.*
64) Marder K, Stern Y, Malouf R, Tang M-X, Bell K, Dooneief G, el Sadr W, Goldstein S, Gorman J,
McMurtry C, Richards M, Sano M, Sorrell S, Todak G, Ehrhardt A, Mayeux R. Early neurological and
neuropsychological manifestations of HIV infection in a cohort of intravenous drug users. Arch Neurol
1992; 49: 1169-1175.*
65) Mayeux R, Stern Y, Tang M-X, Todak G, Marder K, Sano M, Richards M, Stein A, Ehrhardt A,
Gorman J. Mortality Risks in Gay Men with Human Immunodeficiency Virus infection and Cognitive
Impairment. Neurology 1993; 43: 176-182.*
66) Gorman JM, Mayeux R, Stern Y, Williams JBW, Rabkin J, Goetz RR, Ehrhardt AA. The effect of
zidovudine on neuropsychiatric measures in HIV infected men. Am J Psychiatry 1993; 150: 505-507.
67) Richards M, Stern Y, Marder K, Cote L, Mayeux R. Relationships between extrapyramidal signs and
cognitive function in a community-dwelling cohort of patients with Parkinson's disease and normal
elderly individuals. Ann Neurol 1993; 267-274.*
68) Mayeux R, Ottman R, Tang M-X, Noboa-Bauza L, Marder K, Gurland B, Stern Y. Genetic
Susceptibility and Head Injury as Risk Factors for Alzheimer's Disease Among Community-Dwelling
Elderly Persons and their First-Degree Relatives. Ann Neurol 1993; 33:494-501.*
69) Tatemichi T, Desmond D, Paik M, Figueroa M, Gropen TI, Stern Y, Sano M, Remien R, Williams
JBM, Mohr J, Mayeux R. Clinical determinants of dementia related to stroke. Ann Neurol 1993; 33:568-
70) Stern Y, Marder K, Tang M-X, Mayeux R. Antecedent clinical features associated with dementia in
Parkinson's disease. Neurology 1993; 46:1690-1693.*
71) Richards M, Bell K, Dooneief G, Marder K, Sano M, Mayeux R, Stern Y. Patterns of
neuropsychological performance in Alzheimer's disease patients with and without extrapyramidal signs.
Neurology 1993; 46: 1708-1711.*
72) Stern Y, Richards M, Sano M, Mayeux R. Comparison of cognitive changes in patients with
Alzheimer's and Parkinson's disease. Arch Neurol 1993; 50: 1040-1045.*
Mayeux -12

73) Mayeux R, Stern Y, Ottman R, Tatemichi TK, Tang M-X, Maestre G, Ngai C, Tycko B, Ginsberg H.
The apolipoprotein ε4 allele in patients with Alzheimer's disease. Ann Neurol 1993; 34:752-754.*
74) Richards M, Stern Y, Mayeux R. Subtle extrapyramidal signs can predict the development of
dementia in elderly individuals. Neurology 1993; 43: 2184-2188.*
75) Richards M, Marder K, Cote L, Mayeux R. Interrater reliability of the United Parkinson's disease
Rating Scale. Mov Disorders 1994; 9:89-91.*
76) Mayeux R, Tang M-X, Marder K, Cote LJ, Stern Y. Smoking and Parkinson's disease. Mov
Disorders 1994; 9: 207-212.*
77) Stern Y, Gurland B, Tatemichi TK, Tang M-X, Wilder D, Mayeux R. Influence of education and
occupation on the incidence of dementia. JAMA 1994; 271:1004-1010.*
78) Marder K, Maestre G, Cote LJ, Mejia H, Alfaro B, Halim A, Tang M-X, Tycko B, Mayeux R. The
apolipoprotein-ε4 allele in Parkinson's disease with and without dementia. Neurology 1994; 44 1330-
79) Schupf N, Dapell D, Lee J, Ottman R, Mayeux R. Increased risk for Alzheimer's disease in mothers
of adults with Down syndrome. Lancet 1994; 344:353-356.*
80) Lynch T, Sano M, Marder KS, Bell KL, Foster NL, Defendini RF, Sima AAF, Koehane C, Nygaard
TG, Fahn S, Mayeux R, Rowland LP, Wilhelmsen KC. Clinical Characteristics of a family with
chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology 1994;
81) Tatemichi TK, Paik M, Bagiella E, Desmond DW, Stern Y, Sano M, Hauser WA, Mayeux R. Risk of
dementia after stroke in a hospitalized cohort: Results of a longitudinal study. Neurology 1994; 44: 1885-
82) Sano M, Rosen W, Stern Y, Rosen J, Mayeux R. Simple reaction time as a measure of global
attention in Alzheimer's disease. JINS 1995; 1: 56-61.
83) Stern Y, Alexander G, Prohovnik I, Stricks L, Link B, Lennon MC, Mayeux R. Relationship
between lifetime occupation and parietal flow: Implications for a reserve against Alzheimer's disease
pathology. Neurology 1995; 55-60.*
84) Schofield PW, Mosesson RE, Stern Y, Mayeux R. The age at onset of Alzheimer's disease and the
intracranial area measurement: a relationship. Arch Neurol 1995; 52: 95-98.*
85) Marder K, Liu X, Dooneief G, Bell K, Schofield P, Sacktor N, Todak G, Friedman R, Ehrhardt A,
Stein Z, Gorman J, Mayeux R. Neurological signs and symptoms in a cohort of gay men followed for 4.5
years. Neurology 1995;45: 261-267.*
86) Maestre G, Ottman R, Stern Y, Gurland B, Chun M, Tang M-X, Shelanski M, Tycko B, Mayeux R.
Apolipoprotein-Ε and Alzheimer's Disease: Ethnic Variation in Genotypic Risks. Ann Neurol 1995; 37:
Mayeux -13

87) Mayeux R, Ottman R, Maestre G, Ngai C, Tang M-X, Ginsberg H, Chun M, Tycko B, Shelanski MS.
Synergistic effects of Traumatic Head Injury and Apolipoprotein-ε4 in Patients with Alzheimer's
Disease. Neurology 1995; 45:555-557.*
88) Gurland B, Wilder D, Cross P, Lantigua R, Teresi J, Bolivar M, Barret V, Mayeux R. Relative rates
of dementia by multiple case definitions, over two prevalence periods, in three cultural groups. Am J
Geriatric Psych 1995; 3:6-12.*
89) Stern Y, Tang M-X, Denaro J, Mayeux R. Increased Risk of Mortality in Alzheimer’s Disease
patients with more advanced educational and occupational attainment. Ann Neurol 1995; 37: 590-595.*

90) Sacktor N, Prohovnik I, Van Heertum RL, Dooneief G, Gorman J, Marder K, Todak G, Stern Y,
Mayeux R. Cerebral Tc-99m HMPAO SPECT abnormalities in HIV-1-infected gay men without
cognitive impairment. Arch Neurol 1995; 52: 607-611.*
91) Sacktor N, Liu X, Popescu M, Marder K. Stern Y, Mayeux R. Serum neopterin predicts HIV-related
mortality but not progression to AIDS or development of neurological disease in gay men and parenteral
drug users. Arch Neurol 1995; 52:676-679.*
92) Marder K, Tang M-X, Cote LJ, Stern Y, Mayeux R. The frequency and associated risk factors for
dementia in patients with Parkinson' s disease. Arch Neurol 1995; 52:695-701.*
93) Gurland BJ, Wilder DE, Chen J, Lantigua R, Mayeux R, Van Nostrand J. A flexible system of
detection for Alzheimer’s disease and related dementias. Aging Clin Exp Res 1995; 7: 165-172.
94) Jacobs DM, Marder K, Cote LJ, Sano M, Stern Y, Mayeux R. Neuropsychological characteristics of
preclinical dementia in Parkinson’s disease. Neurology 1995; 45: 1691-1696.*
95) Mayeux R, Marder K, Cote LJ, Denaro J, Hemenegildo N, Mejia H, Tang M-X, Lantigua R, Wilder
D, Gurland B, Hauser A. The frequency of idiopathic Parkinson's disease among middle-aged and elderly
Black, Hispanic and White men and women in northern Manhattan 1988 to 1993. Am J Epidemiol 1995;
142: 820-827.*
96) Alexander GE, Prohovnik I, Sackeim HA, Stern Y, Mayeux R. Cortical perfusion and gray-matter
weight in frontal lobe dementia. J Neuropschiat Clin Neurosci 1995;7:188-196.*
97) Sacktor N, Van Heertum RL, Dooneief G, Gorman J, Khandji A, Marder K, Nour R, Todak G, Stern
Y, Mayeux R. A comparison of cerebral SPECT abnormalities in HIV-positive homosexual men with
and without cognitive impairment. Arch Neurol 1995; 52; 1170-1173.*
98) Louis ED, Marder K, Cote LJ, Pullman, Ford B, Wilder D, Tang M-X, Lantigua R, Gurland B,
Mayeux R. Difference in the prevalence of essential tremor among elderly African-Americans, Whites
and Hispanics in Northern Manhattan, NY. Arch Neurol 1995; 52; 1201-1205.*
99) Tang M-X, Tsai W-Y, Marder K, Mayeux R. Linear rank tests for doubly censored data. Statistics
Medicine 1995; 14: 2555-2563.*
Mayeux -14

100) Schofield PW, Tang M-X, Marder K, Bell K, Dooneief G, Lantigua R, Wilder D, Gurland B, Stern
Y, Mayeux R. Consistency of clinical diagnosis in a community-based longitudinal study of dementia
and Alzheimer's disease. Neurology 1995; 45: 2159-2164.*
101) Albert SM, Gurland B, Maestre G, Jacobs DM, Stern Y, Mayeux R. APOE Genotype influences
functional status among elderly without dementia. Am J Med Genet (Neuropsychiatr Genet) 1995;
102) Louis ED, Marder K, Cote L, Wilder D, Tang M-X, Lantigua R, Gurland B, Mayeux R. Prevalence
of a history of shaking in persons 65 years of age and older: diagnostic and functional correlates. Mov
Disord 1996; 11: 63-69.*
103) Logroscino G, Marder K, Cote LJ, Tang M-X, Mayeux R. Dietary lipids and antioxidants in
Parkinson's disease: a population-based, case-control study. Ann Neurol 1996; 39: 89-94.*
104) Tang M-X, Maestre G, Tsai W-Y, Liu X-H, Feng L, Chung W-Y, Chun M, Schofield P, Stern Y,
Tycko B, Mayeux R. Relative Risk of Alzheimer’s Disease and Age-at-Onset Based on APOE Genotypes
Among Elderly African-Americans, Caucasians and Hispanics in New York City. Am J Hum Genetics
1996; 58: 554-574.*
105) Devanand D, Sano M, Tang M-X, Taylor S, Gurland BJ, Wilder D, Stern Y, Mayeux R. Depressed
mood and the incidence of Alzheimer's disease in the community elderly. Arch Gen Psychiatry. 1996; 53:
106) Dooneief G, Marlink R, Bell K, Marder K, Renjifo B, Stern Y, Mayeux R. Neurologic
consequences of HTLV-II infection in injection-drug users. Neurology 1996; 46: 1556-1560.*
107) Marder K, Tang M-X, Alfaro B, Cote L, Louis E, Groves J, Mayeux R. Risk of Parkinson’s disease
among first-degree relatives: A community-based study. Neurology. 1996; 47: 155-160.*
108) Ramachandran G, Marder K, Tang M-X, Schofield PW, Chun MR, Devanand DP, Stern Y,
Mayeux R
. Apolipoprotein-Ε genotype and psychiatric manifestations of Alzheimer's disease. Neurology
1996; 47: 256-259.*
109) Tang M-X., Jacobs D, Stern Y, Marder K, Schofield P, Andrews H, Gurland B, Mayeux R. Effect
of oestrogen during menopause on risk and age-at-onset of Alzheimer’s disease. Lancet 1996; 348:429-
110) Tycko B, Nguyen L, Feng L, Chung W-Y, Tang M-X, Stern Y, Mayeux R. Polymorphisms in the
Human Apolipoprotein-J/Clusterin Gene: Ethnic Variation and Distribution in Alzheimer's Disease.
Human Genetics 1996; 98: 430-6.*
111) Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. Clinical
confirmation of the American Academy of Neurology algorithm for HIV 1-associated cognitive/motor
disorder. Neurology 1996; 47:1274-1253.
112) Schupf N, Kapell D, Zigman W, Canto B, Tycko B, Mayeux R. Onset of dementia is associated
Mayeux -15

with Apolipoprotein ε4 in Down syndrome. Ann Neurol 1996; 40: 799-801.*
113) Liu X, Stern Y, Marder K, Stern Y, Dooneief G, Bell K, Todak G, Joseph M, El Sadr W, Williams
JBW, Ehrhardt A, Stein Z, Mayeux R. Gender differences in HIV-related neurological progression in a
cohort of injecting drug users followed for 3.5 years. J Neuro-AIDS; 1996:17-30.*
114) Dooneief GH, Bello JA, Todak GG, Tang M-X, Marder KS, Stern Y, Mayeux R. Serial MRI in
HIV infection with and without neurologic impairment. J Neuro-AIDS 1996; 1: 49-57.*
115) Schofield PW, Tang M-X, Marder K, Bell K, Dooneief G, Chun M, Sano M, Stern Y, Mayeux R.
Alzheimer’s disease following remote head injury: an incidence study. J Neurol, Neurosurg, Psychiatry
1997; 62: 119-124.*
116) Slooter AJC, Tang M-X, van Duijn C, Stern Y, Ott A, Bell K, Breteler MMB, Van Broeckhoven C,
Tatemichi TK, Tycko B, Hofman A, Mayeux R. Apolipoprotein E4 increases the risk of dementia within
patients with stroke. A population-based investigation. JAMA 1997; 277: 818-821.*
117) Evans DA, Beckett LA, Field TS, Feng L, Albert MA, Bennet DA, Tycko B, Mayeux R.
Apolipoprotein E4 and incidence of Alzheimer’s disease in a community population of older persons.
JAMA 1997; 277: 822-824.*

118) Louis ED, Marder K, Cote LJ, Tang M, Mayeux R. Mortality from Parkinson’s disease. Arch
Neurol 1997; 54: 260-264.*
119) Stern Y, Brandt J, Albert M, Jacobs DM, BellK, Marder K, Sano M, Albert S, Castenada CDC,
Bylsma F, Tycko B, Mayeux R. The absence of the apolipoprotein-Ε ε4 allele is associated with a more
aggressive form of Alzheimer’s disease. Ann Neurol 1997; 41: 615-620.*
120) Wilhelmsen K, Mirel D, Marder K, Bernstein M, Naini A, Leal S, Tang M-X, Freyer G, Graziano J,
Mayeux R. Is There a Genetic Susceptibility Locus for Parkinson's Disease on Chromosome 22ql3 ?
Ann Neurol 1997; 41: 813-817.*
121) Logroscino G, Marder K, Graziano J, Freyer G, Slavkovich V, LoIacono N, Cote L, Mayeux R.
Altered systemic iron metabolism in Parkinson's disease. Neurology 1997; 49: 714-717.*
122) Farrer LA, Cupples LA, Haines JL, Hyman BT, Kukull WA, Mayeux R, Myers RH, Pericak-Vance
MA, Risch N, van Duijn CM, APOE and Alzheimer’s Disease Meta Analysis Consortium. Effects of age,
gender and ethnicity on the association between apolipoprotein-E genotype and Alzheimer’s disease.
JAMA 1997; 278:1349-1356.*
123) Hirano M, Shtilbans A, Mayeux R, Davidson MM, DiMauro S, Knowles JA, Schon EA. Apparent
mtDNA heteroplamsy in Alzheimer’s disease patients and in normals due to PCR amplification of
nucleus-embedded mtDNA pseudogenes. Proc Nat Acad Sci 1997; 94: 14894-14899.
124) Pablos-Mendez A, Mayeux R, Ngai C, Shea S, Bergland L. Association of apo-E polymorphism
with plasma lipid levels in a multi-ethnic elderly population. Atherioscler ThombVasc Biol 1997;
Mayeux -16

125) Jacobs DM, Tang M-X, Stern Y, Sano M, Marder K, Bell KL, Schofield P, Dooneief G, Gurland B,
Mayeux R. Cognitive function in nondemented older women who took estrogen after menopause.
Neurology 1998;50:368-373.*
126) Marder K, Logroscino G, Alfaro B, Mejia H, Halim A, Louis E, Cote L, Mayeux R. Environmental
risk factors for Parkinson’s disease in an urban multi-ethnic community. Neurology 1998; 50:279-281.*
127) Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman BT, Crain B, Tang M-X,
Phelps CH, the Alzheimer’s Disease Centers Consortium on APOE and Alzheimer’s Disease. Utility of
the APOE Genotype in the Diagnosis of Alzheimer’s Disease. New Engl J Med 1998; 338; 506-511.*
128) Tang M-X, Stern Y, Marder K, Bell K, Gurland B, Lantingua R, Andrews H, Tycko B, Mayeux R.
APOE Risks and the Frequency of Alzheimer’s Disease Among African-Americans, Caucasians and
Hispanics. JAMA 1998; 279:751-755.*
129) Schupf N, Kapell D, Nightingale B, Rodriquez A, Tycko B, Mayeux R. Eariler onset of Alzheimer’s
disease in men with Down syndrome. Neurology 1998; 50: 991-995.*
130) Marder K, Logroscino G, Tang M-X, Graziano J, Cote L, Louis E, Alfaro B, Mejia H, Slavkovich V,
Mayeux R. Systemic iron metabolism and mortality from Parkinson’s disease. Neurology 1998; 50;
131) Marder K, Tang M-X, Alfaro B, Mejia H, Cote L, Jacobs D, Stern Y, Sano M, Mayeux R.
Postmenopausal estrogen use and Parkinson’s disease with and without dementia. Neurology 1998; 50;
132) Devi G, Marder K, Schofield PW, Tang M-X, Stern Y, Mayeux R. Validity of family history for the
diagnosis of dementia among siblings of patients with late-onset Alzheimer’s disease. Genet Epidemiol
1998; 15: 215-223.*
133) Mirel DB, Marder K, Graziano J, Freyer G, Zhao Q, Mayeux R, Wilhelmsen KC. Characterization
of the human mitochondrial aconitase gene (ACO2). Gene 1998; 213: 205-218.
134) Devanand DP, Marder K, Michaels KS, Sackeim HA, Bell K, Sullivan MA, Cooper TB, Pelton GH,
Mayeux R. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and
disruptive behaviors in Alzheimer’s disease. Am J Psychiatry 1998; 151:1512-1520.*
135) Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston JW. Parkinson’s
disease in twins: An etiologic study. JAMA 1999: 281:341-346.
136) Xu Y, Berglund L, Ramakrishnan R, Mayeux R, Ngai C, Holleran S, Tycko B, Leff T,
Shachter NS. A common Hpa I RFLP of apolipoprotein C-I increases gene transcription and exhibits an
ethnically distinct pattern of linkage disequilibrium with the alleles of apolipoprotein E. Lipid Res 1999;
137) Marder K, Tang MX, Alfaro B, Mejia H, Cote L, Louis E, Stern Y, Mayeux R. Risk of Alzheimer's
disease in relatives of Parkinson's disease patients with and without dementia. Neurology 1999;
Mayeux -17

138) Small SA, Perera M, DeLaPaz R, Mayeux R, Stern Y. Differential regional activation of the
hippocampal formation among elderly with memory decline. Ann Neurol 1999; 45: 466-472.
139) Small SA, Stern Y, Tang M-X, Mayeux R. Selective decline in memory function among healthy
elderly followed prospectively. Neurology 1999; 52: 1392-1396.*
140) Merchant C, Tang M-X, Albert S, Manly J, Stern Y, Mayeux R. The influence of smoking on the
risk of Alzheimer’s disease. Neurology 1999; 52: 1408-1412.*
141) Moroney J, Tang M-X, Stern Y, Lerglund L, Small S, Merchant C, Bell K, Mayeux R. Low-density
lipoprotein cholesterol and the risk of dementia with stroke. JAMA 1999; 282:254-260.*
142) Gurland BJ, Wilder DE, Lantigua R, Stern Y, Chen J, Killeffer EH, Mayeux R. Rates of dementia in
three ethnoracial groups. Int J Geriatr Psychiatry 1999 14:481-93.*
143) Romas S, Tang M-X, Berglund L, Mayeux R. APOE genotype, plasma lipids, lipoproteins and
Alzheimer’s disease in northern Manhattan elderly. Neurology. 1999; 53:517-521.*
144) Mayeux R, Tang M-X, Jacobs DM, Manly J, Bell K, Merchant C, Small SA, Stern Y, Wisniewski
HM, Mehta PD. Plasma amyloid β peptide 1-42 and incipient Alzheimer’s disease. Ann Neurol 1999; 46:
145) Devi G, Ottman R, Tang M-X, Marder K, Stern Y, Tycko B, Mayeux R. Influence of
Apolipoprotein E genotype on familial aggregation of Alzheimer’s disease among Caucasians, African
Americans and Carribean Hispanics in Northern Manhattan. Neurology 1999; 53: 789-794.*
146)Teresi JA, Albert SM, Homes D, Mayeux R. Use of latent class analyses for the estimation of
prevalence of cognitive impairment, and signs of stroke and Parkinson’s disease among African-
Americans elderly of central Harlem: Results of The Harlem Aging Project. Neuroepidemiology. 1999;
147) Massoud F, Devi G, Stern S, Lawton A, Goldman JE, Liu Y, Chin SS, Mayeux R. A
clinicopathological comparison of community-based and clinic-based cohorts of patients with dementia.
Arch Neurol 1999; 56: 1368-1377.*
148) Devi G, Ottman R, Tang M-X, Marder K, Stern Y, Mayeux R. Familial aggregation of Alzheimer’s
disease among Whites, African Americans and Caribbean Hispanics in Northern Manhattan. Arch Neurol
2000; 57: 72-77.*
149) Simon DK, Mayeux R, Marder K, Kowall NW, Beal MF, Johns DR. Mitochondrial DNA mutations
in complex I and tRNA genes in Parkinson’s disease. Neurology 2000; 54: 703-709.
150) Romas SN, Mayeux R, Rabinowitz D, Tang M-T, Rondon H, Lantigua R, Medrano M, Tycko B,
Knowles J. The deletion polymorphism in α-2-macroglobulin is associated with Alzheimer Disease in
Caribbean Hispanics. Neurosci Let 2000; 279:133-136.*
151) Manly JJ, Merchant CA, Jacobs DM, Small SA, Bell K, Ferin M, Mayeux R. Endogenous estrogen
Mayeux -18

levels and Alzheimer’s disease among postmenopausal women. Neurology 2000; 54: 833-837.
152) Kline J, Kinney A, Levin B, Mayeux R, Schupf N, Warburton D. Alzheimer's disease in the parents
of women with trisomic spontaneous abortions. NeuroReport 2000; 11: 795-9.
153) Romas SN, Mayeux R, Tang M-T, Tycko B, Knowles J. No association between a presenilin-1
polymorphism and Alzheimer’s disease. Arch Neurol 2000; 57: 699-702.*
154) Devanand, DP, Michaels-Marston KS, Liu X, Pelton GH, Padilla M, Marder K, Bell K, Stern Y,
Mayeux R. Olfactory deficits in mild cognitive impairment predict Alzheimer’s disease on follow-up.
Am J Psychiatry 2000; 157: 1399-1405. *
155) Devi G, Fotiou A, Jyrinji D, Tycko B, DeArmand S, Rogaeva E, Song Y, Medieros H, Liang Y,
Orlacchio A, Williamson J, St George-Hyslop P, Mayeux R. Novel Presenilin 1 mutations Associated
with Early Onset of Dementia in a Family with Both Early and Late Onset Alzheimer’s disease. Arch
Neurol 2000; 57: 1454-7. *
156) Massoud F, Devi G, Moroney JT, Stern Y, Lawton A, Bell K, Marder K, Mayeux R. The role of
routine laboratory studies and neuroimaging in the diagnosis of dementia: a clinicopathological study. J
Am Geriatric Soc 2000; 48: 1204-10.*
157) Small SA, Wu EX, Bartsch D, Perera GM, Lacefield CO, DeLaPaz R, Mayeux R, Stern Y, Kandel
ER. Imaging Physiologic Dysfunction of Individual Hippocampal Subregions in Humans and Genetically
Modified Mice. Neuron 2000; 28: 653-64.
158) Tang M-X, Cross P, Andrews , Jacobs DM, Small S, Bell K, Merchant C, Lantigua R, Costa R,
Stern Y, Mayeux R. Incidence Rates for Alzheimer’s Disease Among Black, Caribbean Hispanic and
White Elderly Living in Northern Manhattan. Neurology 2000; 56 (1): 49-56. *
159) Schupf N, Patel B, Silverman W, Zigman WB, Zhong N, TyckoB, Mehta PD, Mayeux R. Elevated
plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett
2001; 301:199-203.*
160) Small SA, Nava AS, DeLaPaz R, Mayeux R, Stern Y. Circuit mechanisms underlying memory
encoding and retrieval in the long axis of the hippocampal formation. Nature Neuroscience 2001; 4: 442-
161) Hyman BT, Smith C, Buldyrev I, Whalen C, Brown H, Tang M-X, Mayeux R. Autoantibodies to
Alzheimer disease related Aß. Ann Neurol 2001; 49:808-10.*
162) Mayeux R, Small SA, Tang M-X, Tycko B, Stern Y. Memory Performance in Healthy Elderly
Without Alzheimer’s Disease: Effects of time and Apolipoprotein-ε4. Neurobiology Aging 2001; 22:
163) Rogaeva EA, Fafel KC, Song YQ Medeiros H, Sato C, Liang Y, Richard E, Rogaev EI, Frommelt
P, Sadovnick AD, Meschino W, Boss M, Mayeux R, St George-Hyslop PH. Screening for PS1
mutations in a referral-based series of Alzheimer's Disease cases: 21 Novel mutations. Neurology 2001;
57: 621-5.
Mayeux -19

164) Lee J, Tang M-X, Schupf N, Stern Y, Jacobs DM, Tycko B, Mayeux R. Mortality and
apolipoprotein E in Hispanics, African-Americans and Caucasians. Am J Medical Genetics 2001; 103:
165) Luchsinger JA, Tang M-X, Stern Y, Shea S, Mayeux R. Diabetes and risk of Alzheimer’s disease
and dementia with stroke in a multiethnic cohort. Am J Epidemiology 2001; 154: 635-41.*
166) Schupf N, Kapell D, Nightengale B, Lee JH, Mohlenhoff J, Bewley S Ottman R, Mayeux R.
Specificity of the fivefold increase in AD in mothers of adults with Down Syndrome. Neurology 2001;
57: 979-85.*
167) Athan E, Williamson J, Ciappa A, Santana V, Romas SN, Lee JH, Zadroga HR, Lantigua R,
Medrano M, Torres M, Arawaka S, Rogaeva E, Song Y, Sato C, Kawarai T, Stern Y, St George-Hyslop
P, Tycko B, Mayeux R. A Novel Founder Mutation in Presenilin 1 Causing Early-Onset Alzheimer’s
Disease in Unrelated Caribbean Hispanic Families. JAMA 2001; 286: 1-7.*
168) Khokhar SR, Stern Y, Bell K, Anderson K, Noe E, Mayeux R, Albert SM. Persistent mobility
deficit in the absence of ADL deficit: A risk factor for mortality. J Am Geriatrics Soc 2001; 45: 1539-43.
170) Mayeux R, Lee JH, Romas SN, Mayo D, Santana V, Williamson J, Ciappa A, Rondon HZ, Estevez
P, Lantigua R, Medrano M, Torres M, Stern Y, Tycko B, Knowles JA. Chromosome 12 mapping of Late-
Onset Alzheimer Disease Among Caribbean Hispanics. Am J Human Genetics 2002: 70: 237-44.*
171) Romas SN, Santana V, Williamson J, Ciappa A, Lee JH, Rondon HZ, Estevez P, Lantigua R,
Medrano M, Torres M, Stern Y, Tycko B, Mayeux R. Familial Alzheimer Disease among Caribbean
Hispanics. Arch Neurology; 2002; 59:87-91. *
172) Rodriguez C, Mendez-Pablos A, Palmas W, Lantigua R, Mayeux R, Bergland L. Comparison of
modifiable determinants of lipids and lipoprotein levels among African-Americans, Hispanics and Non-
Hispanic Caucasians >65 years of age and living in New York City. Am J Cardiology 2002; 89: 178-83.
173) Tanner CM, Goldman SM, Aston DA, Ottman R, Ellenberg J, Mayeux R, Langston JW. Smoking
and Parkinson’s disease in twins. Neurology 2002; 58: 581-8.
174) Small SA, Nava SA, Tsai W-Y, DeLaPaz R, Mayeux R, Stern Y. Imaging hippocampal function
across the human life span: is memory decline normal or not? Ann Neurol 2002; 51: 290-5.
175) Posner HB, Tang M-X, Luchsinger J, Lantigua R, Stern Y, Mayeux R. The relationship of
hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology 2002; 58:1175-
176) Albert SM, Glied S, Andrews H, Stern Y, Mayeux R. Primary Care Expenditures for Newly
Diagnosed Alzheimer’s Disease among White, African-American, and Hispanic Elders Living in New
York City. Neurology 2002; 59: 573-8.*
177) Luchsinger JA, Tang M-X, Stern Y, Shea S, Mayeux R. Caloric intake and risk of Alzheimer’s
disease among elderly African-Americans, Caribbean Hispanics and Whites in New York City. Arch
Mayeux -20

Neurol 2002; 59; 1258-63.*
178) Athan ES, Lee JH, Mayeux R, Tycko B. Polymorphisms in the promoter of the human APP gene:
functional evaluation and allele frequencies in Alzheimer’s disease. Arch Neurol 2002; 59: 1793-9.
179) Pressley JC, Louis ED, Tang MX, Cote LJ, Cohen PD, Glied S, Mayeux RM. The Impact of
Comorbid Disease and Injuries on Resource Use and Expenditures in Parkinsonism. Neurology
180) ) Luchsinger JA, Tang M-X, Stern Y, Shea S, Mayeux R. Antioxidant vitamin intake and risk of
Alzheimer’s disease among elderly African-Americans, Caribbean Hispanics and Whites in New York
City. Arch Neurol 2003; 60: 203-8.*
181) Louis E, Luchsinger JA, Tang M-X, Mayeux R. Parkinsonian Signs in a Community Population of
Older People: Prevalence and Associations with Smoking and Coffee Consumption. Neurology 2003; 61:
182) Clark LN, Levy G, Tang M-X, Mejia-Santana H, Ciappa A, Tycko B, Cote LJ, Louis LD, Mayeux
, Marder K. The Saitohin ‘Q7R’ Polymorphism and Tau Haplotype in Multi-ethnic Alzheimer Disease
and Parkinson’s Disease Cohorts. Neurosci Letters 2003; 347: 17-20.
183) Schupf N, Pang D, Patel BN, Silverman W, Schubert R, Lai F, Kline JK, Stern Y, Ferin M, Tycko B,
Mayeux R. Onset of dementia is associated with age at menopause in women with Down syndrome. Ann
Neurol 2003; 54: 433-8. *
184) Davis HP, Small SA, Stern Y, Mayeux R, Feldstein SN, Keller FR. Acquisition, recall, and forgetting of
verbal information in long-term memory by young, middle-aged, and elderly individuals. Cortex 2003;
185) Mayeux R, Honig L, Tang M-X, Manly J, Stern Y, Mehta PD. Plasma amyloid Aβ40 and Aβ42
and Alzheimer’s disease: Relation to stage of disease, age and mortality. Neurology* 2003 11;61:1185-
186) Honig LS, Tang M-X, Albert S, Costa R, Stern Y, Manly JJ, Mayeux R. Stroke and the risk of
Alzheimer's disease. Arch Neurol 2003; 1707-12.*
187) Hoskin E, Tang M-X, Manly J, Mayeux R. Elevated Sex Hormone Binding Globulin in Elderly
Women with Alzheimer’s Disease. Neurobiol Aging. 2004; 25:141-7.*
188) Patel BN, Pang D, Stern Y, Silverman W, Kline JK, Mayeux R, Schupf N. Obesity enhances verbal
memory in postmenopausal women with Down syndrome. Neurobiol Aging. 2004; 25:159-66.
189) Devi G, Williamson J, Massoud F, Anderson K, Stern Y, Devanand DP, Mayeux R. A comparison
of family history of psychiatric disorders among patients with early- and late-onset Alzheimer's disease. J
Neuropsychiatry Clin Neurosci. 2004;16:57-62.*
190) Louis ED, Tang M-X, Mayeux R. Factor structure of parkinsonian signs in the community-dwelling
elderly. Mov Disord. 2004; 19: 268-72.*
Mayeux -21

191) Lee JH, Flaquer A, Stern Y, Tycko B, Mayeux R. The Heritability of Memory as a Phenotypic
Component of Alzheimer’s Disease. Neurology 2004;62: 414-21. *
192) Luchsinger JA, Tang M-X, Shea S, Mayeux R. Alcohol intake and risk of dementia. JAGS 2004;
52: 540-6.*
193) Reitz C, Tang M-X, Luchsinger J, Mayeux R. Relation of Plasma Lipids to Alzheimer’s Disease
and Vascular Dementia. Arch Neurol 2004 ;61: 705-14.
194) Li Q, Athan ES, Yuan E, Rice SL, Vonsattel J-P, Mayeux R, Tycko B. TP73 allelic expression in
human brain and allele frequencies in Alzheimer's disease. BMC Medical Genetics 2004; 5:14.
195) Luchsinger JA, Tang M-X, Shea S, Miller J, Green R, Mayeux R. Plasma homocysteine levels and risk
of Alzheimer’s disease. Neurology 2004; 62: 1972-76*.
196) Clark LN, Afridi S, Mejia-Santana H, Harris J, Louis ED, Cote LJ, Andrews H, Singleton A, De-
Vrieze FW, Hardy J, Mayeux R, Fahn S, Waters C, Ford B, Frucht S, Ottman R, Marder K. Analysis of
an early-onset Parkinson’s disease cohort for DJ-1 mutations. Mov Disord 2004; 19: 796-800.
197) Lee JH, Flaquer A, Estrada-Nadal L, Costa R, Andrews H, Cross P, Lantigua R, Mayeux R. Genetic
influences on life span and survival among elderly African-Americans, Caribbean Hispanics and
Caucasians. Am J Med Gene 2004: 128A: 159-64.*
198) Louis ED, Tang M-X, Mayeux R. Parkinsonian signs in older people in a community-based study:
Risk of incident dementia. Arch Neurol 2004; 61: 1273-6. *
199) Tycko B, Lee JH, Ciappa A, Saxena A, Li C-M, Lin Feng L, Arriaga A, Stern Y, Lantigua R, Yang
L, Shachter NS Mayeux R. APOE and APOC1 promoter polymorphisms and Alzheimer’s disease in
African-Americans and Caribbean Hispanics. Arch Neurol 2004; 61: 1434-9.*
200) Luchsinger JA, Tang M-X, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer’s disease.
Neurology 2004; 63:1187-92. *
201) Lee JH,
Mayeux R , Mayo D, Santana V, Williamson J, Flaquer A, Ciappa A, Rondon HZ, Estevez
P, Lantigua R, Kawari T, Toulina A, Medrano M, Torres M, Stern Y, Tycko R, Rogaeva E, St George-
Hyslop, Knowles JA. Fine mapping of 10q and 18q for familial Alzheimer disease in Caribbean
Hispanics. Mol Psychiatry 2004; 9:1042-51.*
202) Pressley JC, Tang MX, Marder K, Cote LJ, Mayeux R. Disparities in the recording of Parkinson's
disease on death certificates. Mov Disord 2004 ; 20:315-321.*
203) Schupf N, Costa R, Tang M-X, Andrews H, Tycko B, Lee JH, Mayeux R. Preservation of cognitive
and functional ability as markers of longevity. Neurobio Aging 2004; 25:1231-40*
204) Honig L, Kukul B, Mayeux R. Atherosclerosis and AD: Analysis of data from the US national
Alzheimer’s Coordinating Center. Neurology 2005; 64: 494-500.*
Mayeux -22

205) Louis ED, Tang MX, Schupf N, Mayeux R. Functional correlates and prevalence of mild
parkinsonian signs in a community population of older people. Arch Neurol. 2005; 62:297-302. *
206) Schupf N, Costa R, Luchsinger J, Tang MX, Lee JH, Mayeux R. Relationship between plasma
lipids and all-cause mortality in nondemented elderly. J Am Geriatr Soc. 2005;53:219-26. *
207) Reitz C, Luchsinger J, Tang MX, Manly J, Mayeux R. Impact of plasma lipids and time on memory
performance in healthy elderly without dementia. Neurology. 2005; 64: 1378-83.*
208) Louis ED, Schupf N, Manly J, Marder K, Tang MX, Mayeux R. Association between mild
parkinsonian signs and mild cognitive impairment in a community. Neurology. 2005; 64: 1157-61.*
209) Devanand DP, Pelton GH, Zamora D, Liu X, Tabert MH, Goodkind M, Scarmeas N, Braun I, Stern
Y, Mayeux R. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with
mild cognitive impairment. Arch Neurol. 2005; 62 :975-80.*
210) Clark LN, Nicolai A, Afridi S, Harris J, Mejia-Santana H, Strug L, Cote LJ, Louis ED, Andrews H,
Waters C, Ford B, Frucht S, Fahn S, Mayeux R, Ottman R, Marder K. Pilot association study of the beta-
glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. Mov Disorders
2005; 20:100-3.
211) Luchsinger J, Reitz C, Honig LS, Tang M-X, Mayeux R. Aggregation of vascular risk factors and risk
of Alzheimer’s disease. Neurology; 2005: 65: 545-51.*
212) Reitz C, Luchsinger J, Tang MX, Mayeux R. Effect of smoking and time on cognitive function in
the elderly without dementia. Neurology. 2005; 65: 870-5. *
213) Albert SM, Simone B, Brassard A, Stern Y, Mayeux R. Medicaid home care services and survival
in New York City. Gerontologist. 2005; 45: 609-16.*
214) Schupf N, Tang MX, Albert SM, Costa R, Andrews H, Lee JH, Mayeux R. Decline in cognitive and
functional skills increases mortality risk in nondemented elderly. Neurology 2005; 65:1218-26.*
215) Manly JJ, Bell-McGinty S, Tang M-X, Schupf N, Stern Y, Mayeux R. Implementing diagnostic
criteria and estimating frequency of Mild Cognitive Impairment in an urban community. Arch Neurol.
216) Rippon GA, Tang M-X, Lee JH, Lantigua R, Mayeux R.Familial Alzheimer Disease in Caribbean
Hispanics: Interaction Between Stroke, Estrogen Replacement and APOE. Neurology 2006; 66:35-40.*
217) Shibata N, Kawarai T, Lee JH, Shibata E, Salehi-Rad S, Sato C, Morgan A, Mayeux RP, Rogaeva
E, St George-Hyslop PH. Genetic study of cholesterol metabolism genes (CH25H, ABCA1 and CH24H)
in Alzheimer's disease. Neuroscience Letters 2006; 391:142-6.
218) Reitz C, Luchsinger JA, Tang MX, Manly J, Mayeux R. Stroke and memory performance in elderly
persons without dementia. Arch Neurol 2006; 63:571-6.
Mayeux -23

219) Scarmeas N, Stern Y, Tang M-X, Mayeux R, Luchsinger JA. Mediterranean diet and risk of
Alzheimer’s disease. Ann Neurol 2006; 59: 912-21.
220) Honig LS, Schupf N, Lee JH, Flores I, Tang M-X, Mayeux R. Short telomere repeat length is
associated with mortality and dementia. Ann Neurol. 2006; 60: 181-7.
221) Schupf N, Winsten S, Patel B, Pang D, Ferin M, Zigman WB, Silverman W, Mayeux R.
Bioavailable estradiol and age at onset of Alzheimer's disease in postmenopausal women with Down
syndrome. Neuroscience Letters 2006; 406: 298-302.
222) Olarte L, Schupf N, Lee JH, Tang M-X, Santana V, Williamson J, Tycko B, Maramreddy P, Mayeux R.
APOE-ε4 and Age-At-Onset of Sporadic and Familial Alzheimer Disease in Caribbean Hispanics. Arch
Neurology 2006; 63: 1586-90.*
223) Lee JH, Cheng R, Santana V, Williamson J, Lantigua R, Medrano M, Arriaga A, Stern Y, Tycko B,
Rogaeva E, Wakutani Y, Kawarai T, St George-Hyslop P, Mayeux R. Expanded Genome-Wide Scan
Implicates a Novel Locus at 3q28 Among Caribbean Hispanics with Familial Alzheimer’s Disease. Arch
Neurology 2006; 63: 1591-8. *
224) Elbaz A, Nelson L, Payami H, Ioannidis JPA, Fiske BK, Annesi G, Carmine A, Factor SA, Ferrarese
C, Hadjigeorgiou GM, Higgins D, Kawakami H, Krueger P, Marder K, Mayeux R, Mellick G, Nutt J,
Ritz B, Samii A, Tanner CM, Van Broeckhoven C, Van Den Eeden SK, Wirdefeldt K, Zabetian CP,
Dehem M, Montimurro JS, Myers RM, Southwick A, Trikalinos TA. Lack of replication of thirteen
single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study.
Lancet Neurology 2006; 5:917-23.
225) Luchsinger JA, Miller J, Green R, Tang M-X, Mayeux R. Higher folate intake is related to lower
risk of Alzheimer’s disease in the elderly. Arch Neurol 2007; 64: 86-92.
226) Scarmeas N, Stern Y, Mayeux R, Luchsinger JA. Mediterranean diet, Alzheimer's disease and
vascular mediation. Arch Neurol. 2006; 63: 1707-17.
227) Rogaeva E, Meng Y, Lee JH, Gu Y-J, Kawarai T, Katayama T, Erlich P, Baldwin CT, Cheng R,
Tycko B, Hasegawa H, Chen F, Shibata N, Lunetta K, Cupples LA, Green RC, Sato C, Ruan X, Salehi-
Rad S, Liang Y, Pinessi L, Rainero I, Sorbi S, Bruni A, Duara R, Hampe W, Bujo H, Song Y, Fraser PE,
Westaway D, Schmitt-Ulms G, Mayeux R, Farrer LA, St George-Hyslop P. The sortilin-related receptor
SORLA is functionally and genetically associated with Alzheimer's disease. Nat Genetics 2007; 39:168-
228) Devanand DP, Pradhaban G, Liu X, Khandji A, De Santi S, Segal S, Rusinek H, Pelton GH, Honig
LS, Mayeux R, Stern Y, Tabert MH, de Leon MJ. Hippocampal and entorhinal atrophy in mild
cognitive impairment: prediction of Alzheimer disease. Neurology. 2007; 68 :828-36.
229) Luchsinger JA, Patel B, Tang MX, Schupf N, Mayeux R. Measures of adiposity and dementia risk
in elderly persons. Arch Neurol 2007; 64: 392-8. *
230) Lee JH, Cheng R, Schupf N, Manly JJ, Lantigua R, Stern Y, Rogaeva E, Wakutani Y, Farrer L St
George-Hyslop P , Mayeux R. The Association Between Genetic Variants in SORL1 and Alzheimer's
Mayeux -24

Disease in an Urban, Multiethnic, Community-Based Cohort. Arch Neurol; 64:501-6.*
231) Luchsinger JA, Reitz C, Patel B, Tang MX, Mayeux R. Relation of diabetes to mild cognitive
impairment. Arch Neurol; 64:570-5.*
232) Luchsinger JA, Tang MX, Miller J, Green R, Mehta PD, Mayeux R. Relation of plasma
homocysteine to plasma amyloid beta levels. Neurochem Res 2007; 32:775-81*
233) Reitz C, Patel B, Tang MX, Manly J, Mayeux R, Luchsinger JA. Relation between vascular risk
factors and neuropsychological test performance among elderly persons with Alzheimer's disease.
J Neurol Sci. 2007 Jun 15;257(1-2):194-201.
234) Reitz C, Brickman AM, Luchsinger JA, Wu WE, Small SA, Tang M-X, Mayeux R. Frequency of
subclinical heart disease in elderly persons with dementia. AJGC 2001; 16:183-8.*
235) Shibata N, Kawarai T, Meng Y, Lee JH, Shibata E, Sato C, Sorbi S, Bruni AC, Duara R, Mayeux R,
Farrer LA, St George-Hyslop P, Rogaeva E. Association studies between the plasmin genes and late-onset
Alzheimer's disease. Neurobiol Aging 207; 28: 1041-3.

236) Luchsinger JA, Tang MX, Mayeux R. Glycemic Load and Risk of Alzheimer's Disease. J Nutr
Health Aging 2007; 11:238-41.*
237) Schupf N, Patel B, Pang D, Zigman WB, Silverman W, Mehta PD, Mayeux R Elevated plasma
amyloid β-peptide Aβ42, incident dementia and mortality in Down syndrome. Arch Neurol 2007;

Invited Reviews:

1) Mayeux R. Parkinson's disease and dementia. Current Opinion Neurol Neurosurg 1988; 1: 279-283.*
2) Mayeux R. Therapeutic strategies in Alzheimer's disease. Neurology 1990; 40; 175-80.*
3) Mayeux R. Parkinson's disease: a review of cognitive and psychiatric disorders. J Neuropsych
Neuropsychiatr Behav Neuro 1990; 3:3-14.*
4) Mayeux R. Extrapyramidal Disorders and Dementia. Current Opinion in Neurology 1990; 3: 98-102.*
5) Mayeux R. A neurologist's view of a registry for Alzheimer's disease. Aging 1990; :97-9.*
6) Mayeux R. Diagnostic problems in nursing home patients with dementia: Why we should and how we
can improve accuracy. Alzheimer Disease and Related Disorders 1994: 8: S184-S187.*
7) Chun MR, Mayeux R. Alzheimer's Disease. Current Opinion in Neurology 1994; 7: 299-304.*
8) Spencer S, Davis P, DeAngelis L, Denckla M, Mayeux R, Meador K, Price R. Status of Clinical
Research in neurology. Neurology 1995; 45:839-845.
Mayeux -25

9) Mayeux R, Schupf N. Apolipoprotein-Ε and Alzheimer's disease: The implications of progress in
molecular medicine. Am J Public Health 1995; 85: 1280-1284.*

10) American College of Medical Genetics Working Group on APOE Testing in Alzheimer’s Disease.
Statement on the Use of Apolipoprotein E Testing For Alzheimer’s disease. JAMA 1995; 274:1627-
11) National Institute on Aging/Alzheimer’s Association Working Group. Apolipoprotein E genotyping
in Alzheimer’s Disease. Lancet 1996; 347: 1091-1095.
12) Mayeux R. Development of a national prospective study of Alzheimer’s disease. Alzheimer’s
Disease and Related Disorder. Alzheimer Disease and Associated Disorders 1996; 10 (suppl.1): 38-44.*
13) Mayeux R. Evaluation and use of diagnostic tests in Alzheimer’s disease. Neurobiol Aging 1998;
19: 139-143.*
14) Logroscino G, Marder K, Graziano J, Freyer G, Slavkovich V, Lojacono, Cote LJ, Mayeux R.
Dietary iron, animal fat and risk of Parkinson’s disease. Movement Disord 1998; 13: (S1) 13-16.*
15) Mayeux R. Gene-environment interaction in late-onset Alzheimer disease: the role of apolipoprotein-
ε4. Alzheimer Dis Assoc Disord 1998;12 Suppl 3:S10-5
16) Small SA, Mayeux R. A clinical approach to memory decline. J Practical Psychiatry and Behavioral
Health 1999; 5:87-94.*
17) Mayeux R, Sano M. Drug Therapy: The treatment of Alzheimer’s Disease. New Engl J Med 1999;
18) Honig LS, Mayeux R. Natural history of Alzheimer’s disease. Aging Clin Exp Res 2001; 13: 171-
19) Mayeux R. Epidemiology of Neurodegenerative Diseases. Annual Review of Neuroscience. 2003;
26: 81-104.
20) Kennedy JL, Farrer LA, Andreasen NC, Mayeux R, St George-Hsylop P. The Genetics of Common
Adult-onset Neuropsychiatric Disease: Complexities and Conundra? Science 2003; 302:822-6.
21) Lee JH, Mayeux R. Genetics and its use in Alzheimer’s disease. Trends in Evidence-Based
Neuropsychiatry 2003; 5(3): 41-47.
22) Mayeux R. Biomarkers: Potential Uses and Limitations. NeuroRx 2004; 1: 182-8.
23) Luchsinger JA, Mayeux R. Cardiovascular risk factors and Alzheimer’s disease. Curr Atheroscler
Rep 2004; 6: 261-6.
24) Luchsinger JA, Mayeux R. Dietary factors and Alzheimer’s disease. The Lancet Neurology 2004; 3:
Mayeux -26

25) Mayeux R. Mapping the new frontier: complex genetic disorders. J Clin Invest 2005; 115:1404-
26) Mayeux R. Genetic Epidemiology of Alzheimer Disease. Alzheimer Dis Assoc Disord. 2006
July/September;20 Suppl 2:S58-S62.
27) Luchsinger JA, Mayeux R. Adiposity and Alzheimer’s disease. Current Alzheimer Research 2007;
4: 127-134.
1) Mayeux R. Disorders of speech and learned movements: Aphasia and Apraxia. In: Principals of
Neural Science. Kandel, Eric R., Schwartz, James H., (Eds). Elsevier North-Holland, New York, Volume
I 1981, pps. 593-598.
2) Mayeux R. Depression and Dementia in Parkinson's disease. In: Movement Disorders. Butterworths
International Medical Reviews, Marsden CD, and Fahn S (Eds), London, Butterworth Scientific, pps. 75-
99, 1982.*
3) Ilson J, Fahn S, Mayeux R, Cote L: Pergolide in Parkinson's disease. Lisuride and other dopamine
agonists. Calne D, Horowski R, MacDonald RJ, Wuttke W, (Eds), Raven Press. New York; 1983:443-45l.
4) Ilson J, Fahn S, Mayeux R, Cote L, Snider S: Pergolide treatment of Parkinsonism. Experimental
therapeutics of movement disorders. Fahn S, Calne D, Shoulson I, (Eds), Raven Press. New York;
5) Mayeux R. Emotional Changes Associated with Basal Ganglia Disorders. In: Neuropsychology of
Human Emotion. Heilman KM, Satz P, (Eds). Guilford Press, New York; 1983;141-164.*
6) Mayeux R, Stern Y: Intellectual dysfunction and dementia in Parkinson's disease. In: The Dementias.
Mayeux R, Rosen W, (Eds). Raven Press, New York; 1983:211-227.*
7) Mayeux R, Williams JBW, Stern Y, Cote L: Depression and Parkinson's disease. In: Parkinson-
specific Motor and Mental disorders. Hassler RG, Christ JF (Eds). Adv Neurol 1984; New York: Raven
Press, 40: 241-250.*
8) Mayeux R. Behavioral manifestations of movement disorders: Parkinson's disease and Huntington's
disease. In Jankovic J (Ed) Movement Disorders. Neurological Clinics 1984; 2:527-540.
9) Mayeux R and Kandel ER: Natural language, disorders of language and other localizable disorders of
cognitive functioning. In: Principals of Neural Science. Kandel ER, Schwartz JH, (Eds). Elsevier North-
Holland, New York, Second Edition, 1985, pps. 688-702.
10) Mayeux R, Stern Y: Clinical Heterogeneity in patients with dementia of the Alzheimer type.
Alzheimer's and Parkinson's Disease. Fisher, Hanin, Lachman (eds), New York: Raven Press, pps 129-
Mayeux -27

11) Stern Y, Mayeux R. Possible dopaminergic basis for perceptual motor dysfunction. Alzheimer's and
Parkinson's Disease. Fisher, Hanin, Lachman (eds), New York: Raven Press, pps 185-190.*
12) Prohovnik I, Smith G, Sackeim HA, Mayeux R, Stern Y: The early stages of presenile and senile
Alzheimer's disease: Initial studies of disease severity and cerebral blood flow. Alzheimer's and
Parkinson's Disease. Fisher, Hanin, Lachman (eds), New York: Raven Press, pps 233-240.*
13) Stern Y, Mayeux R. Intellectual Impairment in Parkinson's disease. Parkinson's Disease. Yahr &
Bergman (Eds). Raven Press, New York, pps 405-409.*
14) Mayeux R, Stern Y: Depression and Parkinson's disease. Parkinson's Disease. Yahr & Bergman
(Eds). Raven Press, New York, pps 451-456.*
15) Mayeux R. The Mental State. Handbook of Parkinson's Disease. Koller WA (Ed), New York,
Dekker, pps 125-146. 1987.*
16) Marder K, Mayeux, R. Recognition and management of major behavior problems in Parkinson's
disease. The Comprehensive Management of Parkinson's disease. Stern MB, Hurtig HI (eds). New York:
PMA Publishing Co. 1988.*
17) St.George-Hyslop P., Haines J, Farrer L, Tanzi R, Hobbs W, Polinsky RJ, Nee L, Sorbi S, Piacentini
S, Amaducci L, Heston L, Orr H, Fish S, Crapper-McLachlan D, Percy M, Frommelt P, Foncin J-F, Bruni
A, Wexler N, Mayeux R, and others: Molecular Genetics of Autosomal Dominant Familial Alzheimer's
Disease. The Molecular Biology of Alzheimer's Disease. Finch CE, Davies P (Eds), Cold Spring Harbor,
NY, Cold Spring Harbor Lab. Publications, pps 159-68, 1988.
18) Mayeux R. The epidemiology of major forms of dementia in the United States. In: Sinha KK,
Chandra P (eds), Progress in Clinical Neurosciences. Ranchi, India: Catholic Press, 1988; 1:335-347.*
19) Mayeux R. A current analysis of behavioral problems in patients with idiopathic Parkinson's disease.
Movement Dis 1989; 4: 26-37 (Supplement).*
20) Mayeux R. Alzheimer's Disease. Principles of Geriatric Medicine. Hazzard WR, Andres R, Bierman
EL, Blass JP (eds). New York: McGraw-Hill 1989, pps. 934-48.*
21) Mayeux R. The "serotonin" hypothesis for depression in Parkinson's disease. Adv Neurol 1990;
22) Gurland BJ, Mayeux R, Meyers BS. The effectiveness of intervention for the mental health of the
elderly. In: Kane RL, Evans JG, Macfadyen D.(ed): Improving the Health in Older People: A World
View. London, Oxford University, 1990;(16)262-272.
23) Mayeux R. The "Genetics" of Alzheimer's disease. in: Merritt's Textbook of Neurology, Update 7,
Rowland LP (ed), 1991, Lea & Febiger, pps 3-10.*
24) Mayeux R, Kandel E. Disorders of Language: The Aphasias. In: Kandel E, Schwartz J, Jessell TM.
Principles of Neural Science. Third Edition, 1991. Elsevier, New York, pps:839- 851.
25) Marder K, Mayeux R. The Epidemiology of Dementia in Patients with Parkinson's Disease. In: The
Mayeux -28

Basal Forebrain. Napier TC, et al (eds). New York: Plenum Press, 1991, pps.439-45.*
26) Sano R, Mayeux R. The Biochemistry of Depression in Parkinson's Disease. In: Parkinson's
Disease. Neurobehavioral Aspects. Huber SJ, Cummings JL (eds), New York: Oxford University Press,
1992, pps. 229-239.*
27) Mayeux R, Foster N, Rossor M, Whitehouse PJ. The clinical evaluation of patients with dementia.
In: Whitehouse PJ (ed), Dementia, Philadelphia: FA Davis, 1992, pps 92-117.*
28) Civil R, Whitehouse PJ, Lanska D, Mayeux R. Degenerative Dementias. In: Whitehouse PJ (ed),
Dementia, Philadelphia: FA Davis, 1992, pps.167-214.
29) Mayeux R, Tatemichi TK, Sacktor N. The Other Dementias. In: Current Therapy in Neurologic
Disease. Johnson RT, Griffin JW (eds). St. Louis: Decker BC, 1993, pps. 296-301.*
30) Tatemichi TK, Sacktor N, Mayeux R. Dementia Associated with Cerebrovascular Disease, Other
Degenerative Diseases and Metabolic Disorders. In: Katzman R, Terry R, Bick K (eds), Alzheimer's
Disease. New York: Raven Press,1994, pps. 123-166.*
31) Mayeux R, Chun MR. Acquired and Hereditary Dementias. In: Rowland LP (ed), Merritt's Textbook
of Neurology. Ninth edition (1994), pps 677-685.*
32) Sacktor N, Mayeux R. Dementia and Delirium. In: Rowland LP (ed), Merritt's Textbook of
Neurology. Ninth edition (1994), pps 1-8.*
33) Maestre G, Schofield P, Chun M, Tang M-X, Tycko B, Mayeux R. Ethnic Variation in the
Association Between APOE-ε4 and Alzheimer’s Disease: A Follow-up Study. In: Roses AD, Weisgaber
K, Christen Y (eds). Apolipoprotein E and Alzheimer’s Disease. Berlin: Springer-Verlag. 1996, pps 170-
34) Mayeux R, Marder K. Putative Clinical and Genetic Antecedents of Dementia Associated with
Parkinson's Disease. Dementia With Lewy Bodies. New York: Churchill Livingstone, 1996, pps. 33-45.*
35) Tang, M-X, Maestre G, Tsai W-Y, Liu X-H, Feng L, Chung W-Y, Chun M, Schofield P, Stern Y,
Tycko B, Mayeux R. Effect of age, ethnicity and head injury on the association between APOE
genotypes and Alzheimer’s disease. In: Relkin NR, Khachaturian ZS, Gandy S (eds) Apolipoprotein E
Gentoyping in Alzheimer’ s Disease. Annals of the New York Academy of Sciences 1996; 802: 6-15.*
36) Chun MR, Schofield P, Stern Y, Mayeux R. The Epidemiology of Dementia Among the Elderly:
Experience from a Community-Based Registry. Association for Research in Nervous and Mental
Disease. Washington D.C., American Psychiatric Press, 1998, pps.1-26.*
37) Schofield P, Mayeux R. Alzheimer’s Disease: Clinical features, Diagnosis and Epidemiology. In:
Markesberry W. The Neuropathology of Dementing Disease. New York: Oxford University Press, 1998,
pps. 89-105.*
38) Manly JJ, Jacobs DM, Mayeux R. Alzheimer Disease Among Different Ethnic and Racial Groups. In:
Terry RD, Katzman R, Bick KL, Sisodia SS (eds), Alzheimer's Disease. Philadelphia: Lippincott
Mayeux -29

Williams and Wilkins,1999, pps. 117-132.*
39) Mayeux R, Gandy S. Alzheimer’s Disease. In Goldman MB, Hatch MC(eds) Women and Health. San
Diego: Academic Press, 1999 pps. 1227-1238.*
40) Jacobs DM, Stern Y, Mayeux R. Dementia in Parkinson disease, Huntington disease, and other
degenerative conditions. In Feinberg TE, Farah MJ, eds. Patient-Based Approaches to Cognitive
Neuroscience. Cambridge: MIT Press, 2000, pp. 375-383.*
41) Mayeux R. Alzheimer’s Disease. The Dana Guide to Brain Health and Disorders. The Dana Press.
42)Mayeux R. Apolipoprotein-E and the Epidemiology of Alzheimer’s Disease. In: Khoury MJ, Little J,
Burke W. Human Genome Epidemiology: Scientific Basis for Using Genetic Information to Improve
Health and Prevent Disease. Oxford University Press, 2003, pps 365-82.
43) Mayeux R. Alzheimer’s Disease: Epidemiology. In: Kurtzke JF. Neuroepidemiology. Encyclopedia
of the Neurological Sciences. Aminoff MJ, Daroff RB (Eds). Academic Press, 2003.
44) Mayeux R. The Influence of α-tocopherol, Caloric Restriction and Genes on Life Span. In:
Rosenberg R, Prusiner S, DiMauro S, Barchi R and Nestler E (eds), The Molecular and Genetic Basis of
Neurologic and Psychiatric Disease, Third Edition. Butterworth-Heinemann, Woburn, Mass, 2003, pps. 693-
45) Manly JJ, Mayeux R. Ethnic differences in dementia and Alzheimer's disease. In N. A. Anderson, R.
A. Bulatao, and B. Cohen (Eds.) Critical perspectives on racial and ethnic differentials in health in late
life. Washington, DC: National Academies Press. 2004, pps. 95-141.

Case Reports
1) Mayeux R, Fahn S: Strokes and ulcerative colitis. Neurology 1978; 28:571-4.
2) Latovitzki N, Abrams G, Clark C, Mayeux R, Ascherl G, Sciarra D: Cerebral cysticercosis. Neurology
1978; 28:838-42.
3) Mayeux R, Leuders H: Complex partial status epilepticus: case report and proposal for diagnostic
criteria. Neurology 1978; 28:957-62.
4) Mayeux R. Sexual intercourse and transient global amnesia. (Letter) New Eng J Med 1979; 300:854.
5) Mayeux R, Hunter S, Fahn S: More on myoclonus in Alzheimer disease. Ann Neurol 1980; 8:200.
6) Mayeux R, Benson DF: Phantom limb and multiple sclerosis. Neurology 1979; 29:724-26.
7) Mayeux R, Alexander M, Benson F, Brandt J, Rosen J: Poriomania. Neurology 1979; 29: 1616-19.
8) Miranda A, DiMauro S, Eastwood AB, Hays A, Johnson WG, Olarte M, Whitlock R, Mayeux R,
Rowland LP: Lipid Storage myopathy, ichthyosis, steatorrhea. Muscle Nerve 1979; 2:1-13.
Mayeux -30

9) Fahn S, Mayeux R. Unilateral Parkinson's disease and contralateral tardive dyskinesia: A unique case
with successful therapy that may explain the pathophysiology of these two disorders. Neural Trans
(Supplement) 1980; 16:179-85.
10) Burke R, Fahn S, Mayeux R, Weinberg H, Louis K, Wilner JH: Neuroleptic malignant syndrome due
to dopamine-depleting drugs in a patient with Huntington disease. Neurology 1981; 31:1022-6.
11) Mayeux R, Fahn S: Paroxysmal dystonic choreoathetosis in a patient with familial ataxia. Neurology
1982; 32:1184-6.
12) Shale H, Fahn S, Mayeux R. Tics in a patient with Parkinson's disease. Movement Disorders. 1986;

Edited Volumes:

1) Mayeux R, Rosen W: The Dementias. Raven Press, New York; 1983, Volume 38, Advances in
2) Agnoli A, Cahn J, Lassen N, Mayeux R. Senile Dementias. London: John Libbey, 1988.
3) Fahn S, Mayeux R. Progress in Parkinson's disease. Movement Disorders, 4 (Supplement), 1989.
4) Surgeon General Report on Tobacco Use, 1995.
4) Mayeux R, Christen Y. Epidemiology of Alzheimer’s disease: From gene to prevention. Research and
Perspectives in Alzheimer’s Disease. Springer Berlin Heidelberg 1999
5) Hofman A and Mayeux R. Investigating Neurological Disease: Epidemiology for Clinical Neurology.
Cambridge University Press 2001.
6) Institute of Medicine Report. Gulf War and Health: Insecticides and Solvents. The National Academies
Press, Washington DC. 2003.
7) Institute of Medicine Report. Gulf War and Health: Updated Literature Review of Sarin. The National
Academies Press, Washington DC. 2004.

Editorials and Commentaries:

1) Mayeux R. Understanding Alzheimer’s disease: Expect more genes and other things. Ann Neurol
1996; 39: 689-690.
2) Mayeux R, Ottman R. Alzheimer’s disease genetics: home runs and strike outs. Ann Neurol 1998;
44: 716-719.
3) Grodstein F, Mayeux R, Stampfer MJ. Tofu and cognitive function: food for thought J Am Coll Nutr
Mayeux -31

2000; 19: 207-9.
4) Mayeux R, Small SA. Finding the beginning or predicting the future? Arch Neurol 2000; 57: 783-4.
5) Mayeux R. Evil forces and vulnerable brains. Neurology 2000; 28:1428-9.
6) Mayeux R. Can estrogen or selective estrogen-receptor modulators preserve cognitive function in
elderly women? N Engl J Med 2001; 344: 1242-4.
7) Mayeux R. Apolipoprotein E, African Americans and Alzheimer’s Disease. Arch Neurol 2003;
8) Mayeux R. Dissecting the relative influences of genes and the environment in Alzheimer's disease.
Ann Neurol. 2004;55:156-8.
9) Green NS, Mayeux R. The long and short of it: telomeres and the brain. Lancet Neurology 2006;

Relevant Brief Notes:

1) Sano M, Stern Y, Mayeux R, Hartman S, Devanand DP. A standardized technique for establishing the
onset symptoms of probable Alzheimer's disease. J Clin Exp Neuropsychol 1987:9;65.
2) Stern Y, Sano M, Paulson J, Mayeux R. Modified Mini-Mental State Examination: Validity and
Reliability. Neurology 37 (Supp 1); 1987:179.
3) Richards M, Stern Y, Mayeux R. Subtle extrapyramidal signs and incident dementia: A follow-up
analysis. Neurology 1995; 45: 1942.
4) Mayeux R. Apolipoprotein ε4 and head trauma: Synergistic or additive risks? Neurology 46: 889-892.
5) Rosenberg RN, Pedley TA, Baringer JR, Fahn S, Lisak RP, Mayeux R, Olson SF, Ringel SP, Rowland
LP, Selzer ME. At jeopardy: the NIH as we know it. Arch Neurol. 2003; 60:1191-2

Manuscripts In Press or submitted:

1) Reitz C, Tang M-X, Mayeux R, Luchsinger JA. Incident Dementia is preceded by Increases in Systolic
Blood Pressure in the Elderly. (submitted)
2) Mayeux R. Alzheimer’s disease: Epidemiology. (The Handbook of Clinical Neurology, 3rd Series).
3) Luchsinger JA, Patel B, Tang MX, Schupf N, Mayeux R. Body mass index, dementia, and mortality in
the elderly. (J Nutr Health Aging).
4) Muller M, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. Metabolic syndrome and
Mayeux -32

dementia risk in a multiethnic elderly cohort. (Dement Geriatr Cogn Disord).
5) Johnson B, Santana V, Schupf N, Tang M-X, Stern Y, Mayeux R, Lee JH. The Heritability of Abstract
Reasoning in Caribbean Latinos with Familial Alzheimer Disease. (Dement Geriatr Cogn Disord).
6) Moreno H, Wu WE, Lee T, Brickman A, Mayeux R, Brown TR, Small SA. Imaging the Aβ-related
neurotoxicity of Alzheimer’s disease (Arch Neurol).
7) Scarmeas N, Luchsinger JA, Mayeux R, Stern Y. Mediterranean diet and Alzheimer's disease
mortality. (Neurology).
8) Williamson J, Goldman JS, Mayeux R. Genetic research and genetic testing in Alzheimer's disease: a
view from the bridge. (Nat Clin Pract Neurol).*
9) Lee JH, Cheng R, Honig LS, Vonsattel JP, Clark L, Mayeux R. The association between genetic
variants in SORL1 and autopsy-confirmed Alzheimer’s disease. (Neurology)*
10) Lee JH, Cheng R, Rogaeva E, Meng Y, Stern Y, Santana V, Lantigua R, Medrano M, Jimenez-
Velazques I, Farrer LA, St George-Hyslop P , Mayeux R. The chromosome 12p13 locus for late-onset
Alzheimer’s disease. (submitted)*
11) Lee JH, Barral S, Cheng R, Chacon I, Santana V, Williamson J, Lantigua R, Medrano M, Ivonne
Jimenez-Velazques, Stern Y, Tycko B, Rogaeva E, Wakutani Y,Kawarai T, St George-Hyslop P , Mayeux
. Age-at-onset linkage analysis in Caribbean Hispanics with familial late-onset Alzheimer’s disease.



Laser in Conjunction with Endoscopic Forehead Surgery for Soft Tissue Masses Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan Running Title: Laser and Endoscopic surgery ABSTRACT Purpose: The use of the endoscopic techniques in plastic surgery has been a significant turn around of the traditional techniques. However, the combination of the laser with Method

What popped into your mind when you first readsome sense, the nation’s purchasing power has increasedbecause of the availability of those pills. that, too. But as a typical, fun-loving economist I alsoYet the numbers you see on real G.D.P. don’t reflectfound myself wondering how the Commerce Departmentthat increase — and they never will. Eventually Viagrawould account for the wonder

Copyright © 2010 Health Drug Pdf